Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Early Parkinson's Disease Monotherapy With CVN424

ClinicalTrials.gov ID: NCT06006247

Public ClinicalTrials.gov record NCT06006247. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Trial of CVN424 in Early Parkinson's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not taking dopaminergic or anti-PD therapies.

Study identification

NCT ID
NCT06006247
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Cerevance Beta, Inc.
Industry
Enrollment
64 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
30 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 10, 2023
Primary completion
Jan 29, 2025
Completion
Feb 12, 2025
Last update posted
Mar 22, 2026

2023 – 2025

United States locations

U.S. sites
42
U.S. states
20
U.S. cities
32
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35233
Barrow Neurological Institute Phoenix Arizona 85013
St Joseph's Hospital and Medical Center Phoenix Arizona 85013
Muhammad Ali Parkinson Center Phoenix Arizona 85326
Movement Disorders Center of Arizona, LLC Scottsdale Arizona 85258
Parkinson's Research Centers of America - Palo Alto Palo Alto California 94301
CenExel Rocky Mountain Clinical Research Englewood Colorado 80113
Parkinson's Disease and Movement Disorders Center of Boca Raton Boca Raton Florida 33486
SFM Clinical Research, LLC Boca Raton Florida 33487
N1 Research LLC Orlando Florida 32825
Parkinson's Disease Treatment Center of SWFL Port Charlotte Florida 33980
University of South Florida Parkinson's Disease and Movement Disorders Center Tampa Florida 33613
Augusta University Augusta Georgia 30912
University of Kansas Medical Center Kansas City Kansas 66160
University of Kentucky, Dept of Neurology Kentucky Neuroscience Institute Research Lexington Kentucky 40536-0284
University of Kentucky, Center for Clinical and Translational Sciences Lexington Kentucky 40536
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
University of Michigan Hospital / Michigan Clinical Research Unit (MCRU) Cardiovascular Center Ann Arbor Michigan 48109-5872
University of Michigan Department of Neurology Ann Arbor Michigan 48109
Quest Research Institute Farmington Hills Michigan 48334
Struthers Parkinson's Center Golden Valley Minnesota 55427
Albany Medical Center Albany New York 12208
Parkinson's Research Centers of America - Long Island Commack New York 11725
Weill Cornell Medicine New York New York 10021
Icahn School of Medicine at Mount Sinai New York New York 10029
Duke University Medical Center Durham North Carolina 27705
Riverhills Healthcare, Inc dba Riverhills Neuroscience Cincinnati Ohio 45212
The Ohio State University Department of Neurology - Madden Center for Parkinson Disease and Other Movement Disorders Columbus Ohio 43210
The Ohio State University Wexner Medical Center Columbus Ohio 43210
Martha Morehouse Medical Plaza Columbus Ohio 43221
Oregon Health & Science University Portland Oregon 97239
Veracity Neuroscience Memphis Tennessee 38157
Horizon Clinical Research Group Cypress Texas 77429
Texas Movement Disorder Specialists, PLLC Georgetown Texas 78628
Gill Neuroscience Houston Texas 77065
Central Texas Neurology Consultants Round Rock Texas 78681
Inova Neurology - Fairfax Fairfax Virginia 22031
Inova Fairfax Medical Campus Falls Church Virginia 22042
EvergreenHealth Neuroscience Institute Kirkland Washington 98034
EvergreenHealth Research Department Kirkland Washington 98034
Froedtert Hospital Department of Neurology Milwaukee Wisconsin 53226
Medical College of Wisconsin Department of Neurology Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06006247, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 22, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06006247 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →